

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4141482

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the ASSIGNOR'S NAME previously recorded on Reel 039166 Frame 0591. Assignor(s) hereby confirms the NUNC PRO TUNC ASSIGNMENT.
<b>RESUBMIT DOCUMENT ID:</b>	503962106

## CONVEYING PARTY DATA

Name	Execution Date
CONCORDIA PHARMACEUTICALS, LLC	06/29/2016

## RECEIVING PARTY DATA

<b>Name:</b>	KADMON CORPORATION, LLC
<b>Street Address:</b>	KADMON CORPORATION
<b>Internal Address:</b>	450 EAST 29TH STREET
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10016

## PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	8088756

## CORRESPONDENCE DATA

**Fax Number:** (908)654-7866

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (908) 654-5000

**Email:** assignment@lernerdavid.com

**Correspondent Name:** LDLK&M

**Address Line 1:** 600 SOUTH AVENUE WEST

**Address Line 4:** WESTFIELD, NEW JERSEY 07090

<b>ATTORNEY DOCKET NUMBER:</b>	CPHARM 3.3-002
<b>NAME OF SUBMITTER:</b>	MELINDA C. CORMIER
<b>SIGNATURE:</b>	/Melinda C. Cormier/
<b>DATE SIGNED:</b>	11/14/2016

## Total Attachments: 4

source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page1.tif

source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page2.tif

source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page3.tif

source=CPHARM 3.3-002 (6) Assignment Cover Sheet#page1.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3963916

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT
<b>EFFECTIVE DATE:</b>	06/29/2016
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CONCORDIA PHARMACEUTICALS, INC.	06/29/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KADMON CORPORATION, LLC
<b>Street Address:</b>	KADMON CORPORATION
<b>Internal Address:</b>	450 EAST 29TH STREET
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10016
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	8088756
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(908)654-7866
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(908) 654-5000
<b>Email:</b>	assignment@lernerdavid.com
<b>Correspondent Name:</b>	LDLK&M
<b>Address Line 1:</b>	600 SOUTH AVENUE WEST
<b>Address Line 4:</b>	WESTFIELD, NEW JERSEY 07090
<b>ATTORNEY DOCKET NUMBER:</b>	CPHARM 3.3-002
<b>NAME OF SUBMITTER:</b>	CINDY CORB
<b>SIGNATURE:</b>	/Cindy Corb/
<b>DATE SIGNED:</b>	07/15/2016
<b>Total Attachments: 3</b>	
source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page1.tif	
source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page2.tif	
source=CPHARM 3.3-002 (.6) Concordia to Kadmon 6-29-2016#page3.tif	

Exhibit 1

Patent/Application Nos.	Country	Title
14/662,420	US	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
2577310	CA	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	FR	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2218451	FR	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	FR	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
602005021115.2	DE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
602005031528.4	DE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
602005038947.4	DE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	GB	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2218451	GB	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	GB	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	HU	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	IE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	IE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	IT	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	IT	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
278624	MX	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	PL	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	ES	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	ES	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	SE	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP1778209	CH	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
EP2301528	CH	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS
8,088,756	US	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS

### CONFIRMATORY ASSIGNMENT

This Confirmatory Patent Assignment (this "Assignment") dated effective Sept 29 2011 by and between Concordia Pharmaceuticals, LLC, a Florida limited liability company, the successor entity to Concordia Pharmaceuticals, Inc. (the "Assignor"), and Kadmon Corporation, LLC, a Delaware limited liability company (the "Assignee"). Assignor and Assignee are collectively referred to as the "Parties" and individually referred to as a "Party."

WHEREAS, by operation of an Asset Purchase Agreement between the Parties dated December 16, 2011, Assignor has assigned, transferred and conveyed all of its right, title and interest in and to, *inter alia*, (i) all of the patents and patent applications identified on Exhibit 1 of this Assignment (the "Patents") to Assignee for good and valuable consideration, (ii) the right, title and interest in and to any and all divisional, continuation, substitute or reissue applications pertaining to the Patents, (iii) patents applied for or granted worldwide pertaining to the Patents and (iv) the right to sue and collect past damages in connection with the Patents, in the United States and throughout the world (i-iv collectively referred to as the "Patent Rights"), and Assignee agreed to accept the Patent Rights.

Now, THEREFORE, by operation of the Asset Purchase Agreement, Assignor, hereby confirms the above-noted Prior Assignment. Assignor hereby assigned, transferred, conveyed and set over to the Assignee, its successors and assigns, and Assignee accepted, all right, title and interest, in the United States and throughout the world, in and to the Patent Rights, to have and to hold the same, unto Assignee for its own use and enjoyment and for the use and enjoyment of its successors and assigns, for the full term or terms of all such rights. The assignment of the Patents included the right to file domestic patent applications under the laws of the United States and all other countries that claim the benefit of any of the foregoing applications, and to file foreign patent applications in the name of the Assignee or its affiliates, wherever such right may be legally exercised, including the right to claim the benefits of the International Convention for such applications. The Parties confirm the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agreed as follows:


1. Assignor hereby authorizes and requests the United States Commissioner of Patents, and the Patent Office officials in foreign countries as are duly authorized by the respective foreign patent laws to issue patents, to issue any and all patents within the Patent Rights to the Assignee as the owner thereof.
2. Assignor hereby agrees, without further consideration and without expense to the Assignor, to sign all documents and to perform all other lawful acts which the Assignee may reasonably request to make this Assignment of the Patent Rights fully effective.
3. This Assignment shall be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns.
4. This Assignment shall be governed by, and construed in accordance with the laws of the State of New York, U.S.A.
5. This Assignment may be executed and delivered (including electronically) in one or more counterparts, and by the Parties in separate counterparts, each of which when

executed shall be deemed to be an original, but when taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, each of the Parties has caused this Assignment to be executed by its duly authorized representatives on the respective dates entered below.

ASSIGNOR:

Concordia Pharmaceuticals, LLC

By: 

Name: Ronald Hardy

Title: Managing Member

Date: June 29, 2016

ASSIGNEE:

Kadmon Corporation, LLC

By: 

Name: Thomas Gallagher

Title: Senior Vice President

Date: 30 June 2016